

## **prIME Points™**

- ☒ **There are many different mechanisms of resistance to alkylators, steroids, Pls and IMiDs**
- ☒ **We need new tools to evaluate resistance**
- ☒ **There are new classes of agents to overcome resistance (HDAC inhibitors and monoclonal antibodies, etc)**

## prIME Points™

- ✓ Second generation PIs and IMiDs can overcome resistance to the first generation agents
- ✓ Oral agents may improve convenience for our patients
- ✓ Antibodies will be combined with conventional therapy leading to a R-CHOP like approach in treatment of multiple myeloma
- ✓ Therapeutic decisions require evaluation of patient status “fit versus frail”
- ✓ Prompt action when adverse event identified
  - withhold until grade 1
  - reinitiate at lower dose